System and method for determining drug administration information

• US 20070179434A1
• Filed: 12/08/2005
• Published: 08/02/2007
• Est. Priority Date: 12/08/2005
• Status: Active Grant

• Current Assignee: Roche Diabetes Care Inc. (Roche Holding AG)
• Original Assignee: Roche Diagnostics Operations Incorporated (Roche Holding AG)
• Inventors: Weinert, Stefan, Galley, Paul, Wagner, Robin, Chittajallu, Siva, Thukral, Ajay, Buck, Harvey, Marco, Kym, Long, James, Bousamra, Stefan
• Granted Patent: US 7,941,200 B2
• Time in Patent Office: Days
• US Class Current: 604/66
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: G06F 9/451 Execution arrangements for user interfaces
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 20/60 relating to nutrition control, e.g. diets
• CPC Class Codes: G16H 40/63 for local operation
• CPC Class Codes: G16H 40/67 for remote operation

Abstract

A system for determining drug administration information may comprise an input device providing for user input of feed forward information having a first parameter component and a second parameter component, a data storage device and a processor. The data storage device may have stored therein a map correlating values of the first and second parameters to drug administration information. The processor may be responsive to user input of the feed forward information to determine corresponding drug administration information according to the map.

Claims

1. A system for determining drug administration information, the system comprising:

an input device providing for user input of feed forward information having a first parameter component and a second parameter component,

a data storage device having stored therein a map correlating values of the first and second parameter components to drug administration information, and

a processor responsive to user input of the feed forward information to determine corresponding drug administration information according to the map.

2. The system of claim 1 further comprising a display unit,

and wherein the processor is configured to display at least some of the corresponding drug administration information on the display unit.

3. The system of claim 1 wherein the input device includes a display unit,

and wherein the processor is configured to control the display unit to display a graphical user interface having a first axis defined by values of the first parameter component and a second axis defined by values of the second parameter component, the graphical user interface providing for the user input of feed forward information in the form of a single user selection of a corresponding pair of values of the first and second parameter components.

4. The system of claim 3 wherein the graphical user interface includes a touch responsive interface providing for the single user selection of the corresponding pair of values of the first and second parameter components.

5. The system of claim 3 wherein the graphical user interface defines a grid-type user interface providing for the single user selection of discrete pairs of values of the first and second parameter components.

6. The system of claim 3 wherein the graphical user interface defines a continuous function of the first and second parameter components.

7. The system of claim 1 wherein the input device includes a display unit,

and wherein the processor is configured to control the display unit to display a graphical user interface having a first axis defined by a plurality of identifiers of the first parameter component and a second axis defined by values of the second parameter component, the graphical user interface providing for the user input of feed forward information in the form of user selection of pairs of each of the plurality of identifiers of the first parameter component and corresponding values of the second parameter component.

8. The system of claim 7 wherein the graphical user interface includes a touch responsive interface providing for the user selection of the pairs of each of the plurality of identifiers of the first parameter component and corresponding values of the second parameter component.

9. The system of claim 7 wherein the graphical user interface defines a grid-type user interface providing for the user selection of discrete pairs of each of the plurality of identifiers of the first parameter component and corresponding values of the second parameter component.

10. The system of claim 1 wherein the drug is a blood glucose lowering drug.

11. The system of claim 10 wherein the drug is insulin.

12. The system of claim 11 wherein the input device is configured to provide for user input of feed forward information in the form of meal information having the first parameter component corresponding to carbohydrate content and the second parameter component corresponding to an expected speed of overall glucose absorption from the meal by the user.

13. The system of claim 12 wherein the input device includes a display unit,

and wherein the processor is configured to control the display unit to display a graphical user interface having a first axis defined by values of the carbohydrate content values and a second axis defined by values of the expected speed of overall glucose absorption from the meal by the user, the graphical user interface providing for the user input of feed forward information in the form of a single user selection of a corresponding pair of the carbohydrate content and expected speed values.

14. The system of claim 13 wherein the processor is configured to control the display unit to display the values of the carbohydrate content in the form of direct estimates of carbohydrate weight.

15. The system of claim 13 wherein the processor is configured to control the display unit to display the values of the carbohydrate content in the form of meal size values.

16. The system of claim 15 wherein the processor is configured to control the display unit to display the values of the carbohydrate content in the form of meal size values relative to a reference meal size.

17. The system of claim 13 wherein the processor is configured to control the display unit to display the values of the expected speed in the form of meal duration values.

18. The system of claim 17 wherein the processor is configured to control the display unit to display the values of the expected speed in the form of meal duration values relative to a reference meal duration.

19. The system of claim 13 wherein the processor is configured to control the display unit to display the values of the expected speed in the form of total glycemic index values.

20. The system of claim 12 wherein the input device includes a display unit,

and wherein the processor is configured to control the display unit to display a graphical user interface having a first axis defined by values of the carbohydrate content and a second axis defined by values of the expected speed of overall glucose absorption from the meal by the user, the graphical user interface providing for the user input of feed forward information in the form of user selection of corresponding pairs of the carbohydrate content and expected speed values.

21. The system of claim 20 wherein the processor is configured to control the display unit to display the values of the expected speed in the form of a fat amount, a protein amount and a carbohydrate amount, and to display the values of the carbohydrate content in the form of meal size values for each of the fat amount, protein amount and carbohydrate amount.

22. The system of claim 21 wherein the graphical user interface provides for the user input of feed forward information in the form of user selection a meal size value in terms of fat amount, a meal size in terms of protein amount and a meal size in terms of carbohydrate amount.

23. The system of claim 22 wherein the processor is configured to control the display unit to display the meal size values in the form of fat amount, protein amount and carbohydrate amount relative to reference meal size values in terms of fat, protein and carbohydrate amounts respectively.

24. The system of claim 1 wherein the input device is configured to provide for user input of additional feed forward information in the form of exercise information,

and wherein the data storage device has stored therein an additional map correlating the exercise information to modification information,

and wherein the processor is responsive to user input of the exercise information to modify the corresponding drug administration information according to the modification information determined via the additional map.

25. The system of claim 1 wherein the input device is configured to provide for user input of additional feed forward information in the form of user stress information,

and wherein the data storage device has stored therein an additional map correlating the user stress information to modification information,

and wherein the processor is responsive to user input of the stress information to modify the corresponding drug administration information according to the modification information determined via the additional map.

26. The system of claim 1 wherein the input device is configured to provide for user input of additional feed forward information in the form of user illness information,

and wherein the data storage device has stored therein an additional map correlating the user illness information to modification information,

and wherein the processor is responsive to user input of the illness information to modify the corresponding drug administration information according to modification information determined via the additional map.

27. The system of claim 1 wherein the input device is configured to provide for user input of additional feed forward information in the form of user menstrual cycle information,

and wherein the data storage device has stored therein an additional map correlating the user menstrual cycle information to modification information,

and wherein the processor is responsive to user input of the user menstrual cycle information to modify the corresponding drug administration information according to the modification information determined via the additional map.

28. The system of claim 1 wherein the processor is configured to monitor occurrences of user acceptance and rejection of the drug administration information determined according to the map, and to determine whether the system is acceptable for use by the user based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

29. The system of claim 28 wherein, if the processor determines that the system is acceptable for use by the user, the processor is configured to determine whether the system requires recalibration based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

30. The system of claim 1 further comprising means for providing for input of user feedback information,

and wherein the processor is configured to monitor the user feedback information and determine whether the system is acceptable for use by the user based at least in part on the user feedback information.

31. The system of claim 30 wherein, if the processor determines that the system is acceptable for use by the user, the processor is configured to determine whether the system requires recalibration based at least in part on the user feedback information.

32. The system of claim 1 further comprising means for providing for input of health care professional feedback information,

and wherein the processor is configured to monitor the health care professional feedback information and determine whether the system is acceptable for use by the user based at least in part on the health care professional feedback information.

33. The system of claim 32 wherein, if the processor determines that the system is acceptable for use by the user, the processor is configured to determine whether the system requires recalibration based at least in part on the health care professional feedback information.

34. The system of claim 1 further comprising at least one model-based function responsive to measurement of one or more user conditions to estimate another user condition different than the one or more user conditions,

and wherein the processor is configured to monitor the at least one model-based function and determine whether the system is acceptable for use by the user based at least in part on the at least one model-based function.

35. The system of claim 34 wherein, if the processor determines that the system is acceptable for use by the user, the processor is configured to determine whether the system requires recalibration based at least in part on the at least one model-based function.

36. A method of determining drug administration information, the method comprising:

receiving user input of feed forward information, the feed forward information including user specified values of a first parameter component and a second parameter component, and

correlating the user specified values of the first and second parameter components to drug administration information.

37. The method of claim 36 further comprising displaying at least some of the drug administration information on a display unit.

38. The method of claim 36 wherein correlating the user specified values of the first and second parameter components to drug administration information includes processing the user specified values of the first and second parameter components using a map configured to map values of the user specified values of the first and second parameter components to corresponding drug administration information.

39. The method of claim 36 wherein receiving the user input of feed forward information includes receiving the user input of feed forward information via a graphical user interface, the graphical user interface having a first axis defined by values of the first parameter component and a second axis defined by values of the second parameter component.

40. The method of claim 36 wherein the drug is a blood glucose lowering drug.

41. The method of claim 40 wherein the drug is insulin.

42. The method of claim 41 wherein the first parameter component corresponds to carbohydrate content of the meal and the second parameter component corresponds to an expected speed of overall glucose absorption from the meal by the user.

43. The method of claim 42 wherein the values of the first parameter component are displayed on the graphical user interface in the form of carbohydrate weight.

44. The method of claim 42 wherein the values of the first parameter component are displayed on the graphical user interface in the form of meal size values.

45. The method of claim 44 wherein the values of the first parameter component are displayed on the graphical user interface in the form of meal size values relative to a reference meal size.

46. The method of claim 42 wherein the values of the second parameter component are displayed on the graphical user interface in the form of meal duration values.

47. The method of claim 46 wherein the values of the second parameter component are displayed on the graphical user interface in the form of meal duration values relative to a reference meal duration.

48. The method of claim 42 wherein the values of the second parameter component are displayed on the graphical user interface in the form of a fat amount, a protein amount and a carbohydrate amount.

49. The method of claim 48 wherein the values of the first parameter component are displayed on the graphical user interface in the form of meal size values for each of the fat amount, the protein amount and the carbohydrate amount.

50. The method of claim 49 wherein the values of the first parameter are displayed on the graphical user interface in the form of meal size values for each of the fat amount, the protein amount and the carbohydrate amount values relative to reference meal size values for each of the fat amount, the protein amount and the carbohydrate amount respectively.

51. The method of claim 42 wherein the values of the second parameter component are displayed on the graphical user interface in the form of total glycemic index values.

52. The method of claim 36 wherein the first parameter component corresponds to carbohydrate content and the second parameter component corresponds to an expected speed of overall glucose absorption from the meal by the user,

and wherein the method further includes receiving user input of additional feed forward information including user exercise information, and modifying the drug administration information according to the user exercise information.

53. The method of claim 36 wherein the first parameter component corresponds to carbohydrate content and the second parameter component corresponds to an expected speed of overall glucose absorption from the meal by the user,

and wherein the method further includes receiving user input of additional feed forward information including user stress information, and modifying the drug administration information according to the user stress information.

54. The method of claim 36 wherein the first parameter component corresponds to carbohydrate content and the second parameter component corresponds to an expected speed of overall glucose absorption from the meal by the user,

and wherein the method further includes receiving user input of additional feed forward information including user illness information, and modifying the drug administration information according to the user illness information.

55. The method of claim 36 wherein the first parameter component corresponds to carbohydrate content and the second parameter component corresponds to an expected speed of overall glucose absorption from the meal by the user,

and wherein the method further includes receiving user input of additional feed forward information including user menstrual cycle information, and modifying the drug administration information according to the user menstrual cycle information.

56. The method of claim 36 further comprising:

monitoring occurrences of user acceptance and rejection of the drug administration information determined according to the map, and

determining whether the method is acceptable for use by the user based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

57. The method of claim 56 further comprising the following if the method is acceptable for use by the user:

determining whether recalibration of the method is required based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

58. The method of claim 36 further comprising:

monitoring user feedback information that is different than the feed forward information, and

determining whether the method is acceptable for use by the user based at least in part on the user feedback information.

59. The method of claim 58 further comprising the following if the method is acceptable for use by the user:

determining whether recalibration of the method is required based at least in part on the user feedback information.

60. The method of claim 36 further comprising:

monitoring health care professional feedback information, and

determining whether the method is acceptable for use by the user based at least in part on the health care professional feedback information.

61. The method of claim 60 further comprising the following if the method is acceptable for use by the user:

determining whether recalibration of the method is required based at least in part on the health care professional feedback information.

62. The method of claim 36 further comprising:

defining at least one model-based function responsive to measurement of one or more user conditions to estimate another user condition different than the one or more user conditions, and

determining whether the method is acceptable for use by the user based at least in part on the at least one model-based function.

63. The method of claim 62 further comprising the following if the method is acceptable for use by the user:

determining whether recalibration of the method is required based at least in part on the at least one model-based function.

64. A method for determining patient suitability for a graphical user interface configured to allow the patient to select feed forward information from which drug administration information is determined, the method comprising:

collecting patient-relevant information relating to events that are defined any of a number of categories of feed forward information and corresponding drug administration information,

processing the collected patient-relevant information to determine whether one or more regular patterns in the patient-relevant information can be identified that allow acceptable prediction of appropriate values of the drug administration information based on corresponding categories of the feed forward information,

if the one or more regular patterns in the patient-relevant information can be identified, processing the collected patient-relevant information to determine whether the number of categories of feed forward information can be reduced, and

if the number of categories of feed forward information can be reduced, reducing the number of categories of feed forward information.

65. The method of claim 64 further comprising:

pre-screening the patient to determine whether the patient is an acceptable candidate for the graphical user interface, and

executing the collecting step, the two processing steps and the reducing step only if the patient is an acceptable candidate for the graphical user interface.

66. The method of claim 64 wherein processing the collected patient-relevant information to determine whether one or more regular patterns in the patient-relevant information can be identified comprises:

sorting the patient-relevant information according to at least one variable of the patient-relevant information and pooling the patient-relevant information over all remaining variables of the patient-relevant information,

calculating a coefficient of variation for the patient-relevant information relating to the at least one variable, and

determining that the patient-relevant information sorted by the at least one variable allows acceptable prediction of appropriate values of the drug administration information based on corresponding categories of the feed forward information if the coefficient of variation for the patient-relevant information relating to the at least one variable does not exceed a maximum coefficient of variation.

67. The method of claim 66 wherein processing the collected patient-relevant information to determine whether one or more regular patterns in the patient-relevant information can be identified comprises executing the following steps if the coefficient of variation for the patient-relevant information relating to the at least one variable exceeds a maximum coefficient of variation:

sorting the patient-relevant information according to at least one variable of the patient-relevant information and according to at least another variable of the patient-relevant information, and pooling the patient-relevant information over all remaining variables of the patient-relevant information,

calculating coefficients of variation for the patient-relevant information relating to the at least one variable and to the at least another variable, and

determining that the patient-relevant information sorted by the at least one variable and by the at least another variable allows acceptable prediction of appropriate values of the drug administration information based on corresponding categories of the feed forward information if the coefficient of variations for the patient-relevant information relating to the at least one variable and to the at least another variable do not exceed a maximum coefficient of variation.

68. The method of claim 67 wherein processing the collected patient-relevant information to determine whether one or more regular patterns in the patient-relevant information can be identified comprises executing the following step if either of the coefficients of variation for the patient-relevant information relating to the at least one variable and to the at least another variable exceed the maximum coefficient of variation:

executing the sorting, calculating and determining steps using an iteratively finer pooling of the patient-relevant information until none of the corresponding number of coefficients of variation exceed the maximum coefficient of variation.

69. The method of claim 64 wherein processing the collected patient-relevant information to determine whether the number of categories of feed forward information can be reduced comprises:

determining merging scenarios for all of the number of categories of feed forward information,

analyzing each of the merging scenarios to determine whether feed forward categories can be merged according to that merging scenario,

selecting a best merging scenario from each of the merging scenarios that have feed forward categories that can be merged, and

merging feed forward categories according to the best merging scenario.

70. The method of claim 69 further comprising executing the determining, analyzing, selecting and merging steps for each of the one or more regular patterns in the patient-relevant information.

71. The method of claim 64 further comprising:

creating a map that maps the patient-selectable categories of the feed forward information to corresponding drug administration information, and

implementing the map with the graphical user interface.

72. The method of claim 71 further comprising:

monitoring occurrences of user acceptance and rejection of the drug administration information determined according to the map, and

determining whether the graphical user interface is acceptable for use by the user based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

73. The method of claim 72 further comprising the following if the graphical user interface is acceptable for use by the user:

determining whether the graphical user interface requires recalibration based at least in part on the occurrences of user acceptance and rejection of the drug administration information.

74. The method of claim 71 further comprising:

monitoring user feedback information that is different than the feed forward information, and

determining whether the graphical user interface is acceptable for use by the user based at least in part on the user feedback information.

75. The method of claim 74 further comprising the following if the graphical user interface is acceptable for use by the user:

determining whether the graphical user interface requires recalibration based at least in part on the user feedback information.

76. The method of claim 71 further comprising:

monitoring health care professional feedback information, and

determining whether the graphical user interface is acceptable for use by the user based at least in part on the health care professional feedback information.

77. The method of claim 76 further comprising the following if the graphical user interface is acceptable for use by the user:

determining whether the graphical user interface requires recalibration based at least in part on the health care professional feedback information.

78. The method of claim 71 further comprising:

defining at least one model-based function responsive to measurement of one or more user conditions to estimate another user condition different than the one or more user conditions, and

determining whether the graphical user interface is acceptable for use by the user based at least in part on the at least one model-based function.

79. The method of claim 78 further comprising the following if the graphical user interface is acceptable for use by the user:

determining whether the graphical user interface requires recalibration based at least in part on the at least one model-based function.

80. The method of claim 64 wherein the events defined by the feed forward information are meals ingested by the patient,

and wherein the drug is a blood glucose lowering drug.

81. The method of claim 80 wherein the events defined by the feed forward information further include exercise undertaken by the patient.

82. The method of claim 80 wherein the events defined by the feed forward information further include stress experienced by the patient.

83. The method of claim 80 wherein the events defined by the feed forward information further include illness experienced by the patient.

84. The method of claim 80 wherein the events defined by the feed forward information further include the patient'"'"'s menstrual cycle.

85. The method of claim 64 wherein the events defined by the feed forward information are exercise events undertaken by the patient,

and wherein the drug is a blood glucose lowering drug.

86. The method of claim 64 wherein the events defined by the feed forward information are stress events experienced by the patient,

and wherein the drug is a blood glucose lowering drug.

87. The method of claim 64 wherein the events defined by the feed forward information are illness events experienced by the patient,

and wherein the drug is a blood glucose lowering drug.

88. The method of claim 64 wherein the events defined by the feed forward information are menstrual events experienced by the patient,

and wherein the drug is a blood glucose lowering drug.